MAPT and tauopathy: Relevantly, unlike other murine or humanized NH2tau-directed immunotherapeutic antibodies (Yanamandra et al., 2013, 2015; Dai et al., 2015, 2017, 2018; Subramanian et al., 2017; Qureshi et al., 2018), 12A12mAb reacts with the 20–22 kDa neurotoxic NH2-truncated tau but not with the physiological full-length form of protein (Corsetti et al., 2008; Amadoro et al., 2012) advocating its in vivo use as safe, more harmless and personalized medicine treatment to slow progressing human tauopathies.